Page 27 - Read Online

Burlone et al. Hepatoma Res 2020;6:3 I http://dx.doi.org/10.20517/2394-5079.2019.37 Page 9 of 10

20. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 2008;48:380-1.
21. Cussigh A, Falleti E, Fabris C, Bitetto D, Cmet S, et al. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C.
Immunogenetics 2011;63:33-41.
22. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology
2004;127 (5 Suppl 1):S35-50.
23. Simonetti RG, Cammà C, Fiorello F, Politi F, D’Amico G, et al. Hepatocellular carcinoma - a worldwide problem and the major risk
factors. Dig Dis Sci 1991;36:962-72.
24. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, et al. Risk factors for hepatocellular carcinoma among patients with chronic
liver disease. N Engl J Med 1993;328:1797-1801.
25. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from
1990 to 2015 at the global, regional, and national level. JAMA Oncol 2017;3:1683-91.
26. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, et al. Hepatitis C virus related cirrhosis: time to occurrence of
hepatocellular carcinoma and death. Gut 2000;47:131-6.
27. West J, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a
population-based cohort study. Aliment Pharmacol Ther 2017;45:983-90.
28. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
29. Fabris C, Smirne C, Toniutto P, Colletta C, Rapetti R, et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C
and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006;39:339-43.
30. Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver:
a clinical and pathological study. J Gastroenterol Hepatol 2013;28:848-54.
31. Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell
2018;175:1289-306.
32. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009;90:1055-70.
33. Schaefer EA, Chung RT. HCV and host lipids: an intimate connection. Semin Liver Dis 2013;33:358-68.
34. Kuo YH, Kee KM, Wang JH, Hsu NT, Hsiao CC, et al. Association between chronic viral hepatitis and metabolic syndrome in southern
Taiwan: a large population-based study. Aliment Pharmacol Ther 2018;48:993-1002.
35. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to
cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
36. Yoon H, Lee JG, Yoo JH, Son MS, Kim DY, et al. Effects of metabolic syndrome on fibrosis in chronic viral hepatitis. Gut Liver
2013;7:469-74.
37. Dong TS, Aby ES, Benhammou JN, Kawamoto J, Han SH, et al. Metabolic syndrome does not affect sustained virologic response of
direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. World J Hepatol 2018;10:612-21.
38. Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to
IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol 2016;64:19-28.
39. Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection.
N Engl J Med 2018;378:354-69.
40. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB,et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and
noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Int Med 2015;163:1-13.
41. Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in
chronic hepatitis C. J Hepatol 2018;68:663-71.
42. Londoño MC, Garcia-Buey L, Mallolas J, Barril G, Ahumada A, et al. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients
with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical
practice - preliminary data Vie-KinD study. J Hepatol 2017;66:S718-9.
43. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, et al. High incidence of hepatocellular carcinoma following successful
interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65:1070-1.
44. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related
cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
45. ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence
of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.
46. Baumert TF, Berg T, Lim JK, Nelson DR. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges.
Gastroenterology 2019;156:431-45.
47. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
J Hepatol 2018.
48. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, et al. The short-term incidence of hepatocellular carcinoma is not increased after
hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology 2018;67:2244-53.
49. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy:
a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
50. Bagella P, Fiore V, Caruana G, Madeddu G. Editorial - non AIDS-defining malignancies: a new epidemic in HIV-infected population for
the upcoming decades? European review for medical and pharmacological sciences 2017. Eur Rev Med Pharmacol Sci 2017;21:4744-5.
51. Di Benedetto F, Tarantino G, Ercolani G, Baccarani U, Montalti R, et al. Multicenter Italian experience in liver transplantation for